1. Home
  2. BIO vs ITCI Comparison

BIO vs ITCI Comparison

Compare BIO & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIO
  • ITCI
  • Stock Information
  • Founded
  • BIO 1952
  • ITCI 2002
  • Country
  • BIO United States
  • ITCI United States
  • Employees
  • BIO N/A
  • ITCI N/A
  • Industry
  • BIO Biotechnology: Laboratory Analytical Instruments
  • ITCI Biotechnology: Pharmaceutical Preparations
  • Sector
  • BIO Industrials
  • ITCI Health Care
  • Exchange
  • BIO Nasdaq
  • ITCI Nasdaq
  • Market Cap
  • BIO 9.1B
  • ITCI 8.7B
  • IPO Year
  • BIO N/A
  • ITCI N/A
  • Fundamental
  • Price
  • BIO $342.01
  • ITCI $126.89
  • Analyst Decision
  • BIO Strong Buy
  • ITCI Buy
  • Analyst Count
  • BIO 4
  • ITCI 13
  • Target Price
  • BIO $414.00
  • ITCI $100.31
  • AVG Volume (30 Days)
  • BIO 158.1K
  • ITCI 2.9M
  • Earning Date
  • BIO 02-13-2025
  • ITCI 02-20-2025
  • Dividend Yield
  • BIO N/A
  • ITCI N/A
  • EPS Growth
  • BIO N/A
  • ITCI N/A
  • EPS
  • BIO N/A
  • ITCI N/A
  • Revenue
  • BIO $2,580,209,000.00
  • ITCI $613,728,000.00
  • Revenue This Year
  • BIO N/A
  • ITCI $48.41
  • Revenue Next Year
  • BIO $2.92
  • ITCI $38.26
  • P/E Ratio
  • BIO N/A
  • ITCI N/A
  • Revenue Growth
  • BIO N/A
  • ITCI 46.08
  • 52 Week Low
  • BIO $262.12
  • ITCI $62.78
  • 52 Week High
  • BIO $387.99
  • ITCI $128.00
  • Technical
  • Relative Strength Index (RSI)
  • BIO 53.78
  • ITCI 87.18
  • Support Level
  • BIO $335.42
  • ITCI $80.83
  • Resistance Level
  • BIO $351.96
  • ITCI $128.00
  • Average True Range (ATR)
  • BIO 9.09
  • ITCI 2.57
  • MACD
  • BIO 2.06
  • ITCI 4.45
  • Stochastic Oscillator
  • BIO 59.23
  • ITCI 97.65

About BIO Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

About ITCI Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Share on Social Networks: